Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma

Inclusion Criteria: * Advanced, unresectable hepatocellular carcinoma (unsuitable for resection, transplant or ablation) * Age ≥ 18 * Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 * Must have normal organ and marrow function * Childs-Pugh score of A or B7 * Must have measurable/evaluable disease as per RECIST 1.1 criteria * Females of child-bearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. For both males and females, effective methods of contraception must be used throughout the study and for four months following the last dose. * Able to swallow and retain orally administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels. * Must be able to understand and be willing to sign the written informed consent form * No more than 10 lesions in the liver Exclusion Criteria: * Have received radiation therapy, major surgery, other locoregional therapy, within 4 weeks prior to the first date of SBRT * Prior radiotherapy to the region of the liver that would result in excessive doses to normal tissues due to overlap of radiation therapy fields * Prior selective internal radiotherapy/hepatic arterial Yttrium therapy, at any t…